BetterLife Pharma Inc.
BETRF
$0.055
-$0.009-14.06%
| Weiss Ratings | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.01 | |||
| Price History | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -17.66% | |||
| 30-Day Total Return | -36.19% | |||
| 60-Day Total Return | -34.99% | |||
| 90-Day Total Return | -23.72% | |||
| Year to Date Total Return | -27.25% | |||
| 1-Year Total Return | -19.47% | |||
| 2-Year Total Return | -6.78% | |||
| 3-Year Total Return | -56.18% | |||
| 5-Year Total Return | -90.53% | |||
| 52-Week High % Change | -63.33% | |||
| 52-Week Low % Change | 9.56% | |||
| Price | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.15 | |||
| 52-Week Low Price | $0.05 | |||
| 52-Week Low Price (Date) | Mar 24, 2025 | |||
| 52-Week High Price (Date) | Jul 10, 2024 | |||
| Valuation | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 7.13M | |||
| Enterprise Value | 10.30M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.03 | |||
| Earnings Per Share Growth | 34.58% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.99 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.06 | |||
| Enterprise Value/EBITDA (TTM) | -19.16 | |||
| Enterprise Value/EBIT | -2.90 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 146.76M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 1275 West 6th Avenue Vancouver, BC V6H 1A6 | |||
| Website | www.abetterlifepharma.com | |||
| Country | Canada | |||
| Year Founded | 2002 | |||
| Profitability | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -789.35% | |||
| Return on Equity | -- | |||
| Income Statement | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -537.50K | |||
| EBIT (TTM) | -3.55M | |||
| Net Income (TTM) | -3.01M | |||
| Net Income Avl. to Common (TTM) | -3.01M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 399.11% | |||
| EPS Diluted (TTM) | -0.03 | |||
| EPS Diluted Growth (Q YOY) | 330.77% | |||
| Balance Sheet | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 13.40K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 194.70K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -4.77M | |||
| Current Ratio (Q) | 0.046 | |||
| Book Value Per Share (Q) | -$0.06 | |||
| Total Assets (Q) | 194.70K | |||
| Total Current Liabilities (Q) | 4.21M | |||
| Total Debt (Q) | 782.20K | |||
| Total Liabilities (Q) | 4.96M | |||
| Total Common Equity (Q) | -7.17M | |||
| Cash Flow | BETRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 1.61M | |||
| Net Change in Cash (TTM) | -52.20K | |||
| Levered Free Cash Flow (TTM) | -1.38M | |||
| Cash from Operations (TTM) | -1.66M | |||
